The present application relates to methods to improve biomass or lipid production in a microorganism from one or more fatty acid and one or more simple carbon co-substrates. Produced lipids may include unsaturated C.sub.6-C.sub.24 fatty acids, alcohols, aldehydes, and acetates which may be useful as final products or precursors to insect pheromones, fragrances, flavors, and polymer intermediates. The application further relates to recombinant microorganisms modified for improved production of biomass or lipid, or improved lipid selectivity. Also provided are methods of producing one or more lipid using the recombinant microorganisms, as well as compositions comprising the recombinant microorganisms and/or optionally one or more of the product lipid.

The present disclosure relates to biomanufacturing systems for producing an organic product. The present disclosure relates to recombinant microorganisms having an improved organic substrate producing ability, and to recombinant microorganisms having an improved organic product producing ability. A benefit of the systems and recombinant microorganisms disclosed herein can include an ability to separately produce an organic product and an organic substrate that generates a culture impurity during its production. The present disclosure relates to methods of producing an organic product using biomanufacturing systems and recombinant microorganisms disclosed herein.

The present invention relates to an NADPH-regeneration system based on monomeric isocitrate dehydrogenase (IDH) and a use thereof. Specifically, the present invention relates to a recombinant vector including a polynucleotide encoding an isocitrate dehydrogenase recombinant protein derived from Corynebacterium glutamicum (CgIDH) and an isocitrate dehydrogenase recombinant protein derived from Azotobacter vinelandii (AvIDH), a method for producing the recombinant protein, and an NADPH-regeneration system using the recombinant protein produced by the method. In the present invention, the enzyme in a monomeric form that may be efficiently used in the NADPH-regeneration system in the transformant into which the recombinant vector was introduced, was found, and the NADPH-regeneration system using the enzyme in a monomeric form has a very high utility value as biological parts and biocatalyst materials that provides NADPH to the NADPH-dependent enzyme.

Provided herein are methods for making lactones comprising incubating a cellular system expressing a heterologous cytochrome P450 (CYP450) protein with a medium comprising straight chain fatty acids to produce subterminal hydroxy fatty acids, and incubating a yeast cell culture with the subterminal hydroxy fatty acids to produce lactones.

Disclosed herein are genetically engineered hematopoietic cells, which express one or more Krebs cycle modulating polypeptides, and optionally a chimeric receptor polypeptide (e.g., an antibody-coupled T cell receptor (ACTR) polypeptide or a chimeric antigen receptor (CAR) polypeptide) capable of binding to a target antigen of interest. Also disclosed herein are uses of the engineered hematopoietic cells for inhibiting cells expressing a target antigen in a subject in need thereof.

Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of a therapeutic biological molecule, and/or naturally or artificially occurring derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to a therapeutic biological molecule and uses of the same. In some embodiments, the aromatic-cationic peptide comprises 2′,6′-dimethyl-Tyr-D-Arg-Phe-Lys-NH.sub.2, Phe-D-Arg-Phe-Lys-NH.sub.2, or D-Arg-2′,6′-Dmt-Lys-Phe-NH.sub.2.

Disclosed herein are methods and compounds for profiling a lysine reactive protein. Also described herein are methods, compounds, and compositions for identifying a small molecule fragment ligand that interacts with a reactive lysine residue.

The present disclosure provides an Escherichia coli transformant and a method for producing itaconate using the Escherichia coli transformant.

The present invention provides an intranasal glioblastoma therapy with purified perillyl alcohol. Patients with recurrent glioblastoma when treated with perillyl alcohol purified by the disclosed methods showed improved survival when compared to historical controls. Glioblastoma patients with an isocitrate dehydrogenase 1 (IDH1)-mutation showed improved survival when compared with wild-type IDH patients.

The invention provides a genetically modified eukaryotic microorganism for anaerobic production of essential amino acids and optionally the co-production of one or more co-products. The microorganism is genetically modified to redirect carbon flow from PEP via oxaloacetate and asparatate semialdehyde, towards the synthesis of increased amounts of essential amino acids. The microorganism may be genetically modified to produce increased amounts of one or more co-product by enhancing carbon flow from PEP via pyruvate, acetyl CoA and malonyl CoA to produce alcohols and lipids, such as triglycerides, fatty esters, fatty alcohols, fatty aldehydes, fatty amides. The invention provides a method for anaerobic production of essential amino acids using the genetically modified eukaryotic microorganism and optionally co-production of said one or more co-products. The genetically modified eukaryotic microorganism may be used for the anaerobic production of essential amino acids and optionally the co-production of said one or more co-products.